secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001213900-24-034982
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio raises ~$4.8M in registered direct offering with warrants at 10% premium
--------------------------------------------------------------------------------

- Gross proceeds ~$4.8M from sale of 571,592 shares and warrants at $8.32 per unit.
- Warrant exercise price $9.152 (10% premium); warrants accelerate upon positive Phase 2 Alzheimer's top-line data.
- Officers, directors, employees bought ~20% of offering at $8.445 per unit.
- Net proceeds to fund Phase 2 Alzheimer's trial (XPro1595) and Phase 1 prostate cancer trial (INKmune).
- Offering expected to close April 24, 2024; LifeSci Capital as sole placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/0001213900-24-034982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/ea0204329-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-034982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer